AbbVie, North Chicago, Ill.-based pharmaceutical research and development company, is working with Galapagos, Mechelen, Belgium-based pharmaceutical company, to test if Janus kinase inhibitor can be used as a Chrohn's disease treatment, according to a Zenopa report.
Galapagos will begin a phase II trial of the drug with 180 patients in 2014. The companies hope the drug will quickly move to a phase III trial.
More Articles on Gastroenterology:
8 Trends Shaping the Present & Future of Gastroenterology
Dr. Andrew Rhim Receives AGA Digestive Cancer Award, $40k Grant
Boston Scientific to Present Data at Digestive Disease Week
Galapagos will begin a phase II trial of the drug with 180 patients in 2014. The companies hope the drug will quickly move to a phase III trial.
More Articles on Gastroenterology:
8 Trends Shaping the Present & Future of Gastroenterology
Dr. Andrew Rhim Receives AGA Digestive Cancer Award, $40k Grant
Boston Scientific to Present Data at Digestive Disease Week